SrasV1, Main, Exploration, bibRecord, 002370

Inhibitors of SARS-CoV entry - Identification using an internally-controlled dual envelope pseudovirion assay

Identifieur interne : 002370 ( Main/Exploration ); précédent : 002369; suivant : 002371

Inhibitors of SARS-CoV entry - Identification using an internally-controlled dual envelope pseudovirion assay

Auteurs : Yanchen Zhou [États-Unis] ; Juliet Agudelo [États-Unis] ; Kai Lu [États-Unis] ; David H. Goetz [États-Unis] ; Elizabeth Hansell [États-Unis] ; Yen Ting Chen [États-Unis] ; William R. Roush [États-Unis] ; James Mckerrow [États-Unis] ; Charles S. Craik [États-Unis] ; Sean M. Amberg [États-Unis] ; Graham Simmons [États-Unis]

Source :

Antiviral research [ 0166-3542 ] ; 2011.

RBID : Pascal:12-0002103

Descripteurs français

English descriptors

KwdEn :
- Antiviral, Antiviral Agents (pharmacology), Drug Evaluation, Preclinical (methods), Drug Evaluation, Preclinical (standards), Envelope, High throughput screening, High-Throughput Screening Assays (methods), High-Throughput Screening Assays (standards), Humans, Identification, Inhibitor, Microbial Sensitivity Tests (methods), Microbial Sensitivity Tests (standards), Performance evaluation, Pseudovirion, SARS Virus (drug effects), Severe acute respiratory syndrome virus, Technique, Virus Cultivation (methods), Virus Cultivation (standards), Virus Internalization (drug effects).
MESH :
- chemical , pharmacology : Antiviral Agents.
- drug effects : SARS Virus, Virus Internalization.
- methods : Drug Evaluation, Preclinical, High-Throughput Screening Assays, Microbial Sensitivity Tests, Virus Cultivation.
- standards : Drug Evaluation, Preclinical, High-Throughput Screening Assays, Microbial Sensitivity Tests, Virus Cultivation.
- Humans.

Abstract

Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) emerged as the causal agent of an endemic atypical pneumonia, infecting thousands of people worldwide. Although a number of promising potential vaccines and therapeutic agents for SARS-CoV have been described, no effective antiviral drug against SARS-CoV is currently available. The intricate, sequential nature of the viral entry process provides multiple valid targets for drug development. Here, we describe a rapid and safe cell-based high-throughput screening system, dual envelope pseudovirion (DEP) assay, for specifically screening inhibitors of viral entry. The assay system employs a novel dual envelope strategy, using lentiviral pseudovirions as targets whose entry is driven by the SARS-CoV Spike glycoprotein. A second, unrelated viral envelope is used as an internal control to reduce the number of false positives. As an example of the power of this assay a class of inhibitors is reported with the potential to inhibit SARS-CoV at two steps of the replication cycle, viral entry and particle assembly. This assay system can be easily adapted to screen entry inhibitors against other viruses with the careful selection of matching partner virus envelopes.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3205982

Affiliations:

États-Unis
Californie, Floride, Oregon

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Inhibitors of SARS-CoV entry - Identification using an internally-controlled dual envelope pseudovirion assay</title>
<author><name sortKey="Zhou, Yanchen" sort="Zhou, Yanchen" uniqKey="Zhou Y" first="Yanchen" last="Zhou">Yanchen Zhou</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Blood Systems Research Institute, University of California</s1>
<s2>San Francisco, CA 94118</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Laboratory Medicine, University of California</s1>
<s2>San Francisco, CA 94143</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Agudelo, Juliet" sort="Agudelo, Juliet" uniqKey="Agudelo J" first="Juliet" last="Agudelo">Juliet Agudelo</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Blood Systems Research Institute, University of California</s1>
<s2>San Francisco, CA 94118</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lu, Kai" sort="Lu, Kai" uniqKey="Lu K" first="Kai" last="Lu">Kai Lu</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Blood Systems Research Institute, University of California</s1>
<s2>San Francisco, CA 94118</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Goetz, David H" sort="Goetz, David H" uniqKey="Goetz D" first="David H." last="Goetz">David H. Goetz</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Pharmaceutical Chemistry, University of California</s1>
<s2>San Francisco, CA 94158</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hansell, Elizabeth" sort="Hansell, Elizabeth" uniqKey="Hansell E" first="Elizabeth" last="Hansell">Elizabeth Hansell</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Pathology and Sandler Center for Drug Discovery, University of California</s1>
<s2>San Francisco, CA 94158</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chen, Yen Ting" sort="Chen, Yen Ting" uniqKey="Chen Y" first="Yen Ting" last="Chen">Yen Ting Chen</name>
<affiliation wicri:level="2"><inist:fA14 i1="05"><s1>Department of Chemistry, Scripps Florida</s1>
<s2>Jupiter, FL 33458</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Roush, William R" sort="Roush, William R" uniqKey="Roush W" first="William R." last="Roush">William R. Roush</name>
<affiliation wicri:level="2"><inist:fA14 i1="05"><s1>Department of Chemistry, Scripps Florida</s1>
<s2>Jupiter, FL 33458</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mckerrow, James" sort="Mckerrow, James" uniqKey="Mckerrow J" first="James" last="Mckerrow">James Mckerrow</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Pathology and Sandler Center for Drug Discovery, University of California</s1>
<s2>San Francisco, CA 94158</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Craik, Charles S" sort="Craik, Charles S" uniqKey="Craik C" first="Charles S." last="Craik">Charles S. Craik</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Pharmaceutical Chemistry, University of California</s1>
<s2>San Francisco, CA 94158</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Amberg, Sean M" sort="Amberg, Sean M" uniqKey="Amberg S" first="Sean M." last="Amberg">Sean M. Amberg</name>
<affiliation wicri:level="2"><inist:fA14 i1="06"><s1>SIGA Technologies, Inc</s1>
<s2>Corvallis, OR 97333</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Oregon</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Simmons, Graham" sort="Simmons, Graham" uniqKey="Simmons G" first="Graham" last="Simmons">Graham Simmons</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Blood Systems Research Institute, University of California</s1>
<s2>San Francisco, CA 94118</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Laboratory Medicine, University of California</s1>
<s2>San Francisco, CA 94143</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0002103</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 12-0002103 INIST</idno>
<idno type="RBID">Pascal:12-0002103</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000082</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000905</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000091</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000091</idno>
<idno type="wicri:doubleKey">0166-3542:2011:Zhou Y:inhibitors:of:sars</idno>
<idno type="wicri:Area/Main/Merge">002398</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3205982</idno>
<idno type="RBID">PMC:3205982</idno>
<idno type="wicri:Area/Pmc/Corpus">000D91</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000D91</idno>
<idno type="wicri:Area/Pmc/Curation">000D91</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000D91</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000B39</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000B39</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:21820471</idno>
<idno type="wicri:Area/PubMed/Corpus">001483</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001483</idno>
<idno type="wicri:Area/PubMed/Curation">001483</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001483</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001476</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001476</idno>
<idno type="wicri:Area/Ncbi/Merge">002372</idno>
<idno type="wicri:Area/Ncbi/Curation">002372</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002372</idno>
<idno type="wicri:doubleKey">0166-3542:2011:Zhou Y:inhibitors:of:sars</idno>
<idno type="wicri:Area/Main/Merge">002118</idno>
<idno type="wicri:Area/Main/Curation">002370</idno>
<idno type="wicri:Area/Main/Exploration">002370</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Inhibitors of SARS-CoV entry - Identification using an internally-controlled dual envelope pseudovirion assay</title>
<author><name sortKey="Zhou, Yanchen" sort="Zhou, Yanchen" uniqKey="Zhou Y" first="Yanchen" last="Zhou">Yanchen Zhou</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Blood Systems Research Institute, University of California</s1>
<s2>San Francisco, CA 94118</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Laboratory Medicine, University of California</s1>
<s2>San Francisco, CA 94143</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Agudelo, Juliet" sort="Agudelo, Juliet" uniqKey="Agudelo J" first="Juliet" last="Agudelo">Juliet Agudelo</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Blood Systems Research Institute, University of California</s1>
<s2>San Francisco, CA 94118</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lu, Kai" sort="Lu, Kai" uniqKey="Lu K" first="Kai" last="Lu">Kai Lu</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Blood Systems Research Institute, University of California</s1>
<s2>San Francisco, CA 94118</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Goetz, David H" sort="Goetz, David H" uniqKey="Goetz D" first="David H." last="Goetz">David H. Goetz</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Pharmaceutical Chemistry, University of California</s1>
<s2>San Francisco, CA 94158</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hansell, Elizabeth" sort="Hansell, Elizabeth" uniqKey="Hansell E" first="Elizabeth" last="Hansell">Elizabeth Hansell</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Pathology and Sandler Center for Drug Discovery, University of California</s1>
<s2>San Francisco, CA 94158</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chen, Yen Ting" sort="Chen, Yen Ting" uniqKey="Chen Y" first="Yen Ting" last="Chen">Yen Ting Chen</name>
<affiliation wicri:level="2"><inist:fA14 i1="05"><s1>Department of Chemistry, Scripps Florida</s1>
<s2>Jupiter, FL 33458</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Roush, William R" sort="Roush, William R" uniqKey="Roush W" first="William R." last="Roush">William R. Roush</name>
<affiliation wicri:level="2"><inist:fA14 i1="05"><s1>Department of Chemistry, Scripps Florida</s1>
<s2>Jupiter, FL 33458</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mckerrow, James" sort="Mckerrow, James" uniqKey="Mckerrow J" first="James" last="Mckerrow">James Mckerrow</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Department of Pathology and Sandler Center for Drug Discovery, University of California</s1>
<s2>San Francisco, CA 94158</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Craik, Charles S" sort="Craik, Charles S" uniqKey="Craik C" first="Charles S." last="Craik">Charles S. Craik</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Pharmaceutical Chemistry, University of California</s1>
<s2>San Francisco, CA 94158</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Amberg, Sean M" sort="Amberg, Sean M" uniqKey="Amberg S" first="Sean M." last="Amberg">Sean M. Amberg</name>
<affiliation wicri:level="2"><inist:fA14 i1="06"><s1>SIGA Technologies, Inc</s1>
<s2>Corvallis, OR 97333</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Oregon</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Simmons, Graham" sort="Simmons, Graham" uniqKey="Simmons G" first="Graham" last="Simmons">Graham Simmons</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Blood Systems Research Institute, University of California</s1>
<s2>San Francisco, CA 94118</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Department of Laboratory Medicine, University of California</s1>
<s2>San Francisco, CA 94143</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Drug Evaluation, Preclinical (methods)</term>
<term>Drug Evaluation, Preclinical (standards)</term>
<term>Envelope</term>
<term>High throughput screening</term>
<term>High-Throughput Screening Assays (methods)</term>
<term>High-Throughput Screening Assays (standards)</term>
<term>Humans</term>
<term>Identification</term>
<term>Inhibitor</term>
<term>Microbial Sensitivity Tests (methods)</term>
<term>Microbial Sensitivity Tests (standards)</term>
<term>Performance evaluation</term>
<term>Pseudovirion</term>
<term>SARS Virus (drug effects)</term>
<term>Severe acute respiratory syndrome virus</term>
<term>Technique</term>
<term>Virus Cultivation (methods)</term>
<term>Virus Cultivation (standards)</term>
<term>Virus Internalization (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (pharmacologie)</term>
<term>Culture virale ()</term>
<term>Culture virale (normes)</term>
<term>Humains</term>
<term>Pénétration virale ()</term>
<term>Tests de criblage à haut débit ()</term>
<term>Tests de criblage à haut débit (normes)</term>
<term>Tests de sensibilité microbienne ()</term>
<term>Tests de sensibilité microbienne (normes)</term>
<term>Virus du SRAS ()</term>
<term>Évaluation préclinique de médicament ()</term>
<term>Évaluation préclinique de médicament (normes)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term>
<term>Virus Internalization</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Evaluation, Preclinical</term>
<term>High-Throughput Screening Assays</term>
<term>Microbial Sensitivity Tests</term>
<term>Virus Cultivation</term>
</keywords>
<keywords scheme="MESH" qualifier="normes" xml:lang="fr"><term>Culture virale</term>
<term>Tests de criblage à haut débit</term>
<term>Tests de sensibilité microbienne</term>
<term>Évaluation préclinique de médicament</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Drug Evaluation, Preclinical</term>
<term>High-Throughput Screening Assays</term>
<term>Microbial Sensitivity Tests</term>
<term>Virus Cultivation</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Culture virale</term>
<term>Humains</term>
<term>Inhibiteur</term>
<term>Pénétration virale</term>
<term>Tests de criblage à haut débit</term>
<term>Tests de sensibilité microbienne</term>
<term>Virus du SRAS</term>
<term>Virus syndrome respiratoire aigu sévère</term>
<term>Identification</term>
<term>Enveloppe</term>
<term>Pseudovirion</term>
<term>Antiviral</term>
<term>Criblage haut débit</term>
<term>Evaluation performance</term>
<term>Technique</term>
<term>Évaluation préclinique de médicament</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) emerged as the causal agent of an endemic atypical pneumonia, infecting thousands of people worldwide. Although a number of promising potential vaccines and therapeutic agents for SARS-CoV have been described, no effective antiviral drug against SARS-CoV is currently available. The intricate, sequential nature of the viral entry process provides multiple valid targets for drug development. Here, we describe a rapid and safe cell-based high-throughput screening system, dual envelope pseudovirion (DEP) assay, for specifically screening inhibitors of viral entry. The assay system employs a novel dual envelope strategy, using lentiviral pseudovirions as targets whose entry is driven by the SARS-CoV Spike glycoprotein. A second, unrelated viral envelope is used as an internal control to reduce the number of false positives. As an example of the power of this assay a class of inhibitors is reported with the potential to inhibit SARS-CoV at two steps of the replication cycle, viral entry and particle assembly. This assay system can be easily adapted to screen entry inhibitors against other viruses with the careful selection of matching partner virus envelopes.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Californie</li>
<li>Floride</li>
<li>Oregon</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Californie"><name sortKey="Zhou, Yanchen" sort="Zhou, Yanchen" uniqKey="Zhou Y" first="Yanchen" last="Zhou">Yanchen Zhou</name>
</region>
<name sortKey="Agudelo, Juliet" sort="Agudelo, Juliet" uniqKey="Agudelo J" first="Juliet" last="Agudelo">Juliet Agudelo</name>
<name sortKey="Amberg, Sean M" sort="Amberg, Sean M" uniqKey="Amberg S" first="Sean M." last="Amberg">Sean M. Amberg</name>
<name sortKey="Chen, Yen Ting" sort="Chen, Yen Ting" uniqKey="Chen Y" first="Yen Ting" last="Chen">Yen Ting Chen</name>
<name sortKey="Craik, Charles S" sort="Craik, Charles S" uniqKey="Craik C" first="Charles S." last="Craik">Charles S. Craik</name>
<name sortKey="Goetz, David H" sort="Goetz, David H" uniqKey="Goetz D" first="David H." last="Goetz">David H. Goetz</name>
<name sortKey="Hansell, Elizabeth" sort="Hansell, Elizabeth" uniqKey="Hansell E" first="Elizabeth" last="Hansell">Elizabeth Hansell</name>
<name sortKey="Lu, Kai" sort="Lu, Kai" uniqKey="Lu K" first="Kai" last="Lu">Kai Lu</name>
<name sortKey="Mckerrow, James" sort="Mckerrow, James" uniqKey="Mckerrow J" first="James" last="Mckerrow">James Mckerrow</name>
<name sortKey="Roush, William R" sort="Roush, William R" uniqKey="Roush W" first="William R." last="Roush">William R. Roush</name>
<name sortKey="Simmons, Graham" sort="Simmons, Graham" uniqKey="Simmons G" first="Graham" last="Simmons">Graham Simmons</name>
<name sortKey="Simmons, Graham" sort="Simmons, Graham" uniqKey="Simmons G" first="Graham" last="Simmons">Graham Simmons</name>
<name sortKey="Zhou, Yanchen" sort="Zhou, Yanchen" uniqKey="Zhou Y" first="Yanchen" last="Zhou">Yanchen Zhou</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002370 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002370 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:12-0002103
   |texte=   Inhibitors of SARS-CoV entry - Identification using an internally-controlled dual envelope pseudovirion assay
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

Serveur d'exploration SRAS

Inhibitors of SARS-CoV entry - Identification using an internally-controlled dual envelope pseudovirion assay

Inhibitors of SARS-CoV entry - Identification using an internally-controlled dual envelope pseudovirion assay

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.